LINC01871: A Potential Drug Target and Biomarker (G101929531)

Target Name: LINC01871

NCBI ID: G101929531

LINC01871

Other Name(s): LINC01871 variant X1 | Long intergenic non-protein coding RNA 1871, transcript variant X1 | long intergenic non-protein coding RNA 1871

LINC01871: A Potential Drug Target and Biomarker

LINC01871 is a gene that encodes a protein known as long non-coding RNA (lncRNA). The lncRNA has been shown to play a critical role in the development and progression of various diseases, including cancer. As a result, LINC01871 has emerged as a promising drug target and biomarker.

The LINC01871 gene was first identified in the Human Genome Project in 2014. It is located on chromosome 16 and has a length of approximately 2100 nucleotides. The LINC01871 protein is made up of 195 amino acids and has a predicted localization to the nuclear envelope.

Several studies have demonstrated that LINC01871 is involved in various cellular processes, including cell adhesion, migration, and invasion. It has also been shown to play a role in regulating gene expression and has been linked to the development of various diseases, including cancer.

One of the most significant findings related to LINC01871 is its involvement in cancer progression. Studies have shown that LINC01871 is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, LINC01871 has been shown to promote the growth and survival of cancer cells.

Another promising aspect of LINC01871 is its potential as a drug target. Several studies have shown that LINC01871 can be targeted by small molecules, including inhibitors of the protein's activity. These inhibitors have been shown to have a range of effects on cellular processes, including the inhibition of cell adhesion and the inhibition of the formation of blood vessels that feed cancer cells.

In addition to its potential as a drug target, LINC01871 has also been shown to be a valuable biomarker for the diagnosis and prognosis of various diseases. Studies have shown that LINC01871 can be used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

One of the most promising aspects of LINC01871 as a biomarker is its potential to be used for the diagnosis of cancer. Several studies have shown that LINC01871 can be used as a biomarker for the detection of various types of cancer, including breast, ovarian, and prostate cancer. This is because LINC01871 is often expressed in these types of cancer and can be used as a diagnostic tool to identify the presence of cancer.

In addition to its potential as a cancer diagnostic, LINC01871 has also been shown to be involved in the prognosis of various diseases. Studies have shown that LINC01871 has been associated with poor prognosis in various diseases, including cancer. This suggests that LINC01871 may be a useful biomarker for the prediction of disease outcomes.

Overall, LINC01871 is a gene that has the potential to be a drug target and biomarker for various diseases. Further research is needed to fully understand its role in the development and progression of these diseases. However, the studies that have been conducted to date suggest that LINC01871 is a promising molecule that should be further explored.

Protein Name: Long Intergenic Non-protein Coding RNA 1871

The "LINC01871 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01871 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets